AOTMiT: Transparency Council will evaluate drugs for AD and allergy, among others

The agenda includes:

Preparation of positions on:

• The legitimacy of the qualification of the health care service "Comprehensive hospital/ambulatory specialized care for patients allergic to hymenopterous insect venom" as a guaranteed benefit,
• The legitimacy of the qualification of the health care service "Comprehensive outpatient specialized care for patients with allergies treated with specific allergen immunotherapy" as a guaranteed benefit,
• Assessment of the legitimacy of qualifying the health care service "Pediatric emergencycare" as a guaranteed benefit of hospital treatment.

Preparation of positions on drug evaluation:

• Wakix (pitolisantum) for the indication: in adults suffering from narcolepsy with or without cataplexy,
• Adtralza (tralokinumab) under drug program B.124. "Treatment of patients with severe forms of atopic dermatitis (ICD-10: L20)" (adolescent population).

Source: AOTMiT